By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that Clarient has licensed rights to commercialize its DNAarray product portfolio.

The tests are based on array comparative genomic hybridization, and according to CombiMatrix, can provide physicians with "a comprehensive genomic profile of solid cancer tumors and blood-based cancers," which can help guide treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.